ImageneBio (IMA) Common Equity (2020 - 2025)

ImageneBio has disclosed Common Equity across 6 years of filings, most recently posting $133.1 million for Q4 2025.

• Common Equity for Q4 2025 came in at $133.1 million, up 182.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $133.1 million (up 182.92% YoY), and the FY2025 annual result was $133.1 million, up 182.92% from the prior year.
• Common Equity came in at $133.1 million for Q4 2025 at ImageneBio, down from $139.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $227.6 million in Q1 2021 to a low of -$180.4 million in Q2 2025.
• The 5-year median for Common Equity is $143.4 million (2022), against an average of $58.7 million.
• Across the five-year window, Common Equity jumped 434.71% in 2021 and plunged 201.72% in 2024, its largest moves.
• ImageneBio's Common Equity stood at $207.9 million in 2021, then retreated by 29.3% to $147.0 million in 2022, then tumbled by 185.81% to -$126.1 million in 2023, then decreased by 27.32% to -$160.6 million in 2024, then jumped by 182.92% to $133.1 million in 2025.
• The last three Common Equity figures came in at $133.1 million (Q4 2025), $139.8 million (Q3 2025), and -$180.4 million (Q2 2025), per Business Quant data.